Novartis trial failure raises stakes for Amgen and Eli Lilly in Lp(a) drug race
Blood sample for a lipoprotein(a) test. Md Babul Hosen | Istock | Getty Images Novartis‘ failure in a…
FDA approves Gilead HIV pill Bixlenvo designed to simplify treatment
Gilead Bixlenvo drug Courtesy: Gilead The Food and Drug Administration approved a once-daily HIV pill from Gilead that…
Amid the chip bear market, healthcare is breaking out: Chart of the Day
Moderna (MRNA) stock doubled on Wednesday and stole the show. But healthcare had already been quietly breaking out…
CNBC Daily Open: Watching Iran’s economy; a losing game for bonds
Treasury Secretary Scott Bessent speaking to CNBC on May 14th, 2026 from Beijing, China. CNBC Hello, this is…
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of…
We’re increasing our Eli Lilly price target after another beat-and-raise quarter
Eli Lilly on Wednesday reported better-than-expected quarterly results and raised its full-year guidance as the company’s portfolio of…
Eli Lilly (LLY) earnings Q2 2026
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook,…
This GLP-1 stock has bigger opportunities to boost its share price
Instead of betting on which single pharmaceutical company wins a drug race, West Pharmaceutical Services benefits as the…
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its…
Market for psychedelic drugs to treat mental health gets a buy signal
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
Goldman is betting Nvidia will get a boost from health care as industry builds out AI capabilities
Nvidia will get a boost as companies in the health care and life sciences industries increase their push…